THOMAS WIEME: Open Payments
NPI 1427207422 · AUGUSTA, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,213 in 55 payments from 15 companies in 2025. Trend: 2023 $1,921 · 2024 $1,611 · 2025 $1,213
Food & beverage: $1,213
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 17 | $382 |
| ABBVIE INC. | 13 | $187 |
| Lilly USA, LLC | 4 | $139 |
| AstraZeneca Pharmaceuticals LP | 1 | $121 |
| PFIZER INC. | 3 | $69 |
| Abbott Laboratories | 3 | $52 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $41 |
| Dexcom, Inc. | 2 | $41 |
| GlaxoSmithKline, LLC. | 2 | $39 |
| SHIELD THERAPEUTICS INC | 2 | $38 |
Products named: Ozempic, MOUNJARO, AIRSUPRA, UBRELVY, Wegovy, FREESTYLE LIBRE 3, ELIQUIS, QULIPTA.
Industry payments across GA — which companies pay providers there.
